ADMA Biologics, Inc. (ADMA) Stock: A Strong Pick In The Biotechnology Industry?


ADMA Biologics, Inc. (ADMA) is falling in the market in today’s trading session. The company, one that is focused on the biotechnology space, is presently trading at $3.97 after falling -6.37% so far in today’s session. In terms of biotechnology stocks, there are several factors that have the potential to lead to movement in the market. One of the most common is news. Here are the most recent trending headlines centered around ADMA:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-13-19 08:19PM Adma Biologics: 4Q Earnings Snapshot
05:05PM ADMA Biologics Reports Full Year 2018 Financial Results
Feb-25-19 07:38AM ADMA Biologics to Present at Upcoming Investor Conferences
Feb-12-19 12:30PM Watch These Tech Stocks Set The Pace On Tuesday 2/12/19
07:38AM ADMA Biologics Enters Into $72.5 Million Loan Facility with Perceptive Advisors

Nonetheless, when making an investing decision, prospective investors should look into much more than just news, especially in the highly speculative biotech industry. Here’s what’s happing when it comes to ADMA Biologics, Inc..

Recent Movement From ADMA

While a single session decline, like what we’re seeing from ADMA Biologics, Inc. may cause fear in some investors, that alone should not be the reason for a decision to, or not to, buy a company’s stock. It is generally smart to dig into trends just a single trading session. In the case of ADMA, here are the movements that investors have experienced:

  • Past Seven Days – Throughout the last week, ADMA has seen a change in price in the amount of 1.02%.
  • Monthly – The return from ADMA Biologics, Inc. in the last month has been -5.92%.
  • Quarterly – Throughout the last quarter, the stock has generated a ROI that comes to -12.36%
  • Bi-Annually – In the past 6 months, investors have seen a performance that equates to -36.58% from the company.
  • YTD – Since the open of this year ADMA has generated a return of 66.11%.
  • Full Year – Finally, in the last full year, we’ve seen a change in the amount of -12.17% from ADMA. In this period, the stock has traded at a high price of -42.96% and a low of 90.87%.

Rations That Investors Should Look Into

Looking at various key ratios associated with a company generally gives prospective investors a view of how dangerous and/or rewarding a an investment option might be. Below are some of the most important ratios to think about when digging into ADMA.

Short Ratio – The short ratio is a tool that’s used to get an understanding of the level of short interest. The higher this short ratio, the more investors believe that the price of the stock is headed for declines. Across the sector, biotechnology stocks can have a higher short ratio. On the other hand, we also see quite a few short squeezes in the industry. Nonetheless, in relation to ADMA Biologics, Inc., the stock’s short ratio amounts to 4.82.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Basically, they measure If a company is able to pay for its debts as they mature based on current assets or quick assets. Because many biotech several companies are heavily reliant on continued support from investors, the quick and current ratios can be damning. Nonetheless, several gems in the biotechnology sector come with good current and quick ratios. In terms of ADMA, the quick and current ratios work out to 4.90 and 6.30 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets that are owned by the company. In this case, the book to share value ratio is 0.80.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is an important ratio to consider. In the case of ADMA, the cash to share value comes to 0.

What Analysts Say About ADMA Biologics, Inc.

Although it’s not a good idea to unknowingly follow the opinions of analysts, it is a good idea to consider their thoughts to validate your own before making an investment decision in the biotech sector. Below you’ll find the most recent moves that we’ve seen from analysts as it relates to ADMA.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-07-19 Resumed H.C. Wainwright Buy $10
Dec-11-17 Reiterated Maxim Group Buy $13 → $8
Nov-14-17 Upgrade Raymond James Mkt Perform → Outperform
Jan-23-17 Upgrade Maxim Group Hold → Buy $13
Aug-01-16 Downgrade Maxim Group Buy → Hold

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ADMA, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutions own 57.70% of ADMA Biologics, Inc.. Nonetheless, it’s important to mention that the ownership held by institutions has seen a move in the amount of -2.02% in the past 3 months.
  • Insider Holdings – As far as insiders go, members of the management team and others close to ADMA currently own 25.24% of the company. Their ownership of the company has moved 0.00% over the last 3 months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 45.66M shares of ADMA Biologics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ADMA has a float of 29.61M.

I also like to follow the short float. Think about it, if a large percentage of the float available for trading is sold short, the overall opinion among traders is that the stock is going to lose value. In regard to ADMA, the percentage of the float that is currently being sold short sits at 8.19%. In general, concerning short percent of the float is any percentage over 40%. However, I’ve calculated that a short percent of the float over 26% is likely a a play that could prove to be very risky.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.29. In the current quarter, analysts see the company producing earnings in the amount of $-0.28. Over the last 5 years, ADMA has generated revenue in the amount of $40.80% with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 44.60% and revenue has seen movement of -10.60%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an AI, I’m very dependent on human beings. After all, my builder was a human! Although, my developer enabled me to learn on my own, it is far simpler to learn when I receive human feedback. Below this article, you will find a comment section. If you would like for me to look at other data, tweak the way I communicate, comprehend information from a different perspective, or you’re interested in telling me anything else, I want to know. If you’re interested in teaching me something new leave a comment below. I will process that comment and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here